294 related articles for article (PubMed ID: 30578441)
21. Exploring the microRNA profiles as potential diagnostic probes for oligo- and polymetastatic prognosis of lung metastasis(es) patients.
Wang Z; Gao S; Li T; Ma X; Zhu H; Yan H
Medicine (Baltimore); 2018 Jun; 97(23):e10958. PubMed ID: 29879044
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
Triggiani L; Alongi F; Buglione M; Detti B; Santoni R; Bruni A; Maranzano E; Lohr F; D'Angelillo R; Magli A; Bonetta A; Mazzola R; Pasinetti N; Francolini G; Ingrosso G; Trippa F; Fersino S; Borghetti P; Ghirardelli P; Magrini SM
Br J Cancer; 2017 Jun; 116(12):1520-1525. PubMed ID: 28449007
[TBL] [Abstract][Full Text] [Related]
23. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study.
Nicosia L; Franceschini D; Perrone-Congedi F; Molinari A; Gerardi MA; Rigo M; Mazzola R; Perna M; Scotti V; Fodor A; Iurato A; Pasqualetti F; Gadducci G; Chiesa S; Niespolo RM; Bruni A; Cappelli A; D'Angelo E; Borghetti P; Di Marzo A; Ravasio A; De Bari B; Sepulcri M; Aiello D; Mortellaro G; Sangalli C; Franceschini M; Montesi G; Aquilanti FM; Lunardi G; Valdagni R; Fazio I; Scarzello G; Vavassori V; Maranzano E; Maria Magrini S; Arcangeli S; Gambacorta MA; Valentini V; Paiar F; Ramella S; Di Muzio NG; Loi M; Jereczek-Fossa BA; Casamassima F; Osti MF; Scorsetti M; Alongi F
Clin Transl Radiat Oncol; 2023 Mar; 39():100568. PubMed ID: 36935855
[TBL] [Abstract][Full Text] [Related]
24. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
25. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
[TBL] [Abstract][Full Text] [Related]
26. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.
Uppal A; Ferguson MK; Posner MC; Hellman S; Khodarev NN; Weichselbaum RR
Clin Exp Metastasis; 2014 Aug; 31(6):735-48. PubMed ID: 24968866
[TBL] [Abstract][Full Text] [Related]
27. [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results.
Pasqualetti F; Panichi M; Sainato A; Matteucci F; Galli L; Cocuzza P; Ferrazza P; Coraggio G; Pasqualetti G; Derosa L; Sollini M; Mannelli L; Ortori S; Monzani F; Ricci S; Greco C; Fabrini MG; Erba PA
Radiat Oncol; 2016 Jan; 11():9. PubMed ID: 26796633
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
Tsumura H; Ishiyama H; Tabata KI; Sekiguchi A; Kawakami S; Satoh T; Kitano M; Iwamura M
Prostate; 2019 Apr; 79(5):506-514. PubMed ID: 30585345
[TBL] [Abstract][Full Text] [Related]
29. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
[TBL] [Abstract][Full Text] [Related]
30. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
31. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
De Bleser E; Tran PT; Ost P
Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
[TBL] [Abstract][Full Text] [Related]
32. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
Jones DZ; Schmidt ML; Suman S; Hobbing KR; Barve SS; Gobejishvili L; Brock G; Klinge CM; Rai SN; Park J; Clark GJ; Agarwal R; Kidd LR
BMC Cancer; 2018 Apr; 18(1):421. PubMed ID: 29653561
[TBL] [Abstract][Full Text] [Related]
33. [Metastasis-directed therapy in prostate cancer].
Borkowetz A; Hölscher T
Urologie; 2024 Mar; 63(3):225-233. PubMed ID: 38388789
[TBL] [Abstract][Full Text] [Related]
34. microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer.
Zedan AH; Hansen TF; Assenholt J; Pleckaitis M; Madsen JS; Osther PJS
Tumour Biol; 2018 May; 40(5):1010428318775864. PubMed ID: 29775158
[TBL] [Abstract][Full Text] [Related]
35. Oligometastasis: Past, Present, Future.
Gutiontov SI; Pitroda SP; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):530-538. PubMed ID: 32976785
[TBL] [Abstract][Full Text] [Related]
36. [Oligometastatic prostate cancer management].
Kleinclauss F; Thiery-Vuillemin A
Prog Urol; 2019 Jun; 29 Suppl 1():S20-S34. PubMed ID: 31307628
[TBL] [Abstract][Full Text] [Related]
37. Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study.
Christ SM; Pohl K; Muehlematter UJ; Heesen P; Kühnis A; Willmann J; Ahmadsei M; Badra EV; Kroeze SGC; Mayinger M; Andratschke N; Huellner M; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):596-602. PubMed ID: 35908582
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of [
Cysouw M; Bouman-Wammes E; Hoekstra O; van den Eertwegh A; Piet M; van Moorselaar J; Boellaard R; Dahele M; Oprea-Lager D
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):406-410. PubMed ID: 29559285
[TBL] [Abstract][Full Text] [Related]
39. Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.
Jiang Y; Mei W; Gu Y; Lin X; He L; Zeng H; Wei F; Wan X; Yang H; Major P; Tang D
Mol Oncol; 2018 Sep; 12(9):1559-1578. PubMed ID: 30024105
[TBL] [Abstract][Full Text] [Related]
40. Outcomes after a first and/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18-F) choline PET-CT.
Gomez-Iturriaga A; Casquero Ocio F; Ost P; Fernandez I; Rodeño E; Llarena R; Garcia-Olaverri J; Ortiz de Zarate R; Cacicedo J; Ahtamon A; Bilbao P
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13093. PubMed ID: 31115124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
